Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #3 on Aligos Therapeutics Inc (ALGS)
oxnous
01/06/22 4:37 PM
#4 RE: DewDiligence #3
DewDiligence
03/22/22 9:43 AM
#10 RE: DewDiligence #3
Aligos Therapeutics…today announced that it has discontinued development of its drug candidate, ALG-020572, which was being studied in subjects with chronic hepatitis B (CHB). Dosing in the first CHB cohort of Study ALG-020572-401 (NCT05001022) was stopped after one subject experienced a serious adverse event (SAE) with significant increase in alanine aminotransferase (ALT) following multiple dosing of 210 mg ALG-020572 that resulted in a brief hospitalization. This is one of four CHB subjects in this first cohort who experienced potentially drug-related ALT flares…